PR Newswire BiotechOriginal article
FDA Clears CU Anschutz Clinical Trial Using Engineered Immune Cells to Fight Colorectal Cancer
Trial StartCAR T-cell therapyPositive
AI Analysis
Summary
The FDA has granted permission for CU Anschutz researchers to conduct a clinical trial using engineered CAR T-cells designed to target dual pathways that support colorectal tumor growth and immune evasion.
Clinical Trial Data
Outcome Details
FDA granted permission for clinical trial using engineered CAR T-cells targeting dual pathways in colorectal tumors
Importance:5/10
Sentiment:
0.70
CAR-TImmunotherapyColorectal CancerFDA ClearanceClinical Trial
Related Companies
Read the original article
Published by PR Newswire Biotech on September 10, 2026 7:15 PM